Delivery Order SPE2DB22D3016-SPE2DB25FAVT8
- Not listed
- The Defense Logistics Agency awarded a $13,075.97 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens, 40 mg/0.4 mL dosage. This contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a firm fixed-price delivery order valued at $12,837.62 for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This contract award, issued on July 30, 2025, represents a non-competitive child delivery order under an existing indefinite delivery contract vehicle. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 31, 2025. HUMIRA is a widely used...
- The Defense Logistics Agency awarded a $9,257.14 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of HUMIRA (adalimumab) prefilled pens, 40 mg/0.4 mL. This non-competitive, competitively awarded contract is structured as a firm fixed price delivery order with a completion date of July 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its pharmaceutical distribution...
- The Defense Logistics Agency awarded a delivery order valued at $9,063.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 5, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single...
- The Defense Logistics Agency awarded a $4,843.93 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. The contract represents a single delivery order...
- The Defense Logistics Agency awarded a $1,510.60 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL on June 3, 2025, with performance in Conshohocken, Pennsylvania. This is a firm fixed price, non-set-aside contract with a completion date of June 4, 2025. The delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through...
- The Defense Logistics Agency awarded a delivery order valued at $37,698.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of May 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL doses. This is a firm fixed price delivery order with no set-aside designation, demonstrating that the award was competitively procured. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. HUMIRA is a widely...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order was placed with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used biologic immunosuppressant medication indicated for...
- The Defense Logistics Agency Medical Supply Chain awarded a $17,277.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens containing 40 mg/0.4 mL of pharmaceutical product. The contract, awarded on June 16, 2025, with an ultimate completion date of June 17, 2025, represents a non-competitive, non-set-aside procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FAVT8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,948.66 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens containing 40 mg/0.4 mL doses. This competitive award, issued on May 6, 2025, with an ultimate completion date of May 7, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be performed and sourced from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This prime contract vehicle provides comprehensive global pharmaceutical support to military healthcare programs, enabling the contractor to supply a broad range of medications, specialty pharmaceuticals, vaccines, and related medical supplies to support the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. HUMIRA is a widely used biologic immunosuppressant commonly prescribed for rheumatoid arthritis, psoriasis, and other autoimmune conditions, making it a standard component of military medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 5/6/25 |